Recent studies have shown that molecular expression patterns in MBC differ from those in female breast cancer (FBC), with a frequent expression of (hormone receptors [HRs]; estrogen receptor [ER], progesterone receptor [PgR], and androgen receptor [AR]) and greater sensitivity to hormonal therapies [1–4]. This evidence concerns the gene AR and breast carcinoma.